ACCESS Newswire
10 May 2022, 00:31 GMT+10
Findings shared at the American Society of Andrology 47th Annual Conference in La Jolla, Calif
BERKELEY, CA / ACCESSWIRE / May 9, 2022 / YourChoice Therapeutics, a startup based in Berkeley, California, presented data demonstrating the efficacy of YCT-529 as a novel non-hormonal male contraceptive in non-human primates, rats and dogs. Additional data were presented from safety studies conducted in rats and dogs. Based on this promising animal data, the company is planning to initiate clinical trials in men as early as late 2022.
YourChoice Therapeutics is developing a novel, orally-available small molecule, YCT-529, that inhibits a protein called retinoic acid receptor-alpha (RAR-alpha). This protein is one of a family of three nuclear receptors that bind retinoic acid, a form of vitamin A that plays important, and well understood, roles in cell growth and differentiation including sperm cell development. The routine administration of YCT-529 halts sperm production without any side effects in the animals studied.
In late March, researchers at The University of Minnesota, presented a poster at the Annual Meeting of the American Chemical Society (ACS) summarizing that YCT-529 was 99% effective as a contraceptive in male mice with a return to full fertility once treatment ended. In early May, YourChoice Therapeutics presented data showing a reduction in sperm production in mice and every species dosed with YCT-529, including rats, dogs, and non-human primates (cynomolgus monkey).
The sperm counts of monkeys that received daily oral doses of YCT-529 fell below the threshold of fertility within two weeks. Once dosing was stopped, sperm counts returned to normal levels observed prior to dosing. Similarly, in rats and dogs, sperm production was inhibited within two weeks. Nadja Mannowetz, PhD, Chief Scientific Officer at YourChoice Therapeutics, noted 'These results represent a significant milestone in the field of contraceptive research. Bringing an effective, safe, and reversible non-hormonal male method to the clinic is the next step to giving men and women more options for family planning.'
In addition to the efficacy data, the company sharedhttps://pr.report/tiRUo3Pr initial safety data indicating that rats and dogs tolerated daily dosing for 14 days at an order of magnitude greater than the therapeutic dose in mice. The company will initiate IND-enabling studies in Q2 2022 and plans to initiate clinical trials at the end of this year or early next year.
About YourChoice Therapeutics
YourChoice Therapeutics was established in 2018 with a focus on developing non-hormonal contraceptives for women leveraging a deep understanding of sperm biology. Its pipeline has evolved and currently the team is developing the small molecule YCT-529 as the first non-hormonal oral contraceptive for men. YCT-529 is a new chemical entity with an established initial safety profile and efficacy in various animal models. YCT-529 as a male contraceptive works by blocking a particular Vitamin A receptor vital for sperm development. Animal studies have demonstrated that routine administration of the compound works quickly, with dogs showing zero sperm count within two weeks and primates falling below fertile levels within the same timeframe. The company believes YCT-529 has the potential to be a convenient and discrete oral male contraceptive product with a greater contraceptive effect than condoms.
For more information visit yourchoicetx.com
Media Contact:
Jennifer Horspool
949-933-4300
[email protected]
SOURCE: YourChoice Therapeutics
Get a daily dose of Detroit Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Detroit Star.
More InformationISTANBUL/PARIS/BRUSSELS: As searing temperatures blanket much of Europe, wildfires are erupting and evacuation orders are being issued...
VENICE, Italy: Over the weekend, hundreds of protesters marched through the narrow streets of Venice to voice their opposition to billionaire...
PARIS, France: France is taking stronger steps to reduce smoking. A new health rule announced on Saturday will soon ban smoking in...
WASHINGTON, DC - U.S. President Donald Trump on Tuesday claimed Elon Musk's success has been built on government subsidies. Without...
EVERGLADES, Florida: Over the weekend, a diverse coalition of environmental activists, Native American leaders, and residents gathered...
BEIJING, China: China's national soccer team may struggle to stir excitement, but its humanoid robots are drawing cheers — and not...
Belarusian President Alexander Lukashenko says the US could order Zelensky to suspend strikes if it truly seeks to end the conflict...
In his second term, President Donald Trump has not taken many actions that draw near-universal praise from across the political spectrum....
Detroit,[US], June 29 (ANI): Three birdies on the back nine helped Akshay Bhatia make the cut on the line at the Rocket Classic on...
The Democratic Republic of the Congo (DRC) and Rwanda signed a historic peace agreement in Washington on Friday to end years of armed...
The European Commission president has been under scrutiny over a multi-billion-dollar Covid-19 vaccine deal A group of lawmakers...
When the online review platform Yelp added a Black-owned tag in 2020, it boosted the visibility of Black-owned restaurants in Detroit....